Cancer Immunotherapy: Chapter 19. Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab

Cancer Immunotherapy: Chapter 19. Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab
ISBN-10
012805915X
ISBN-13
9780128059159
Series
Cancer Immunotherapy
Category
Medical
Pages
684
Language
English
Published
2013-06-04
Publisher
Elsevier Inc. Chapters
Authors
Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok

Description

Ipilimumab is the first drug to show a survival benefit for patients with advanced melanoma and was approved by the US Food and Drug Administration in March of 2011. Ipilimumab enhances antitumor immunity by enhancing T-cell function by blocking the negative regulatory molecule, cytotoxic T-lymphocyte antigen 4 (CTLA-4). Unlike traditional cancer therapy, ipilimumab’s effects may be delayed and occur after initial apparent disease progression. A distinct set of side effects have been described, and ongoing efforts continue to characterize immunologic changes associated with patients who benefit from therapy. Efforts to characterize ipilimumab’s clinical activity in malignancies other than melanoma are ongoing.

Similar books